BALA CYNWYD, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Agiliti, Inc. (NYSE – AGTI)
Under the terms of the Merger Agreement, Agiliti will be acquired by Thomas H. Lee Partners, L.P. (“THL”). THL will acquire all outstanding shares of Agiliti common stock not currently owned by THL and its affiliates and certain management shareholders for $10.00 per share in cash, implying an enterprise value of approximately $2.5 billion. The investigation concerns whether the Agiliti Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration offers fair value to the Company’s shareholders. For example, the deal consideration is below the 52-week high of $19.59 for the Company’s shares and $4.00 per share less than the April 2021 IPO price at which THL took the Company public.
Additional information can be found at https://www.brodskysmith.com/cases/agiliti-inc-nyse-agti/.
Landos Biopharma, Inc. (Nasdaq – LABP)
Under the terms of the agreement, Landos Biopharma will be acquired by AbbVie Inc. (“AbbVie”) (NYSE - ABBV). AbbVie will acquire Landos Biopharma at a price of $20.42 per share in cash, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. The investigation concerns whether the Landos Biopharma Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration offers fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/landos-biopharma-inc-nasdaq-labp/.
Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
Under the terms of the agreement, Fusion will be acquired by AstraZeneca PLC (Nasdaq - AZN), which will, through a subsidiary, acquire all of Fusion's outstanding shares for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right (CVR) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. The upfront cash portion of the consideration represents a transaction value of approximately $2 billion. The investigation concerns whether the Fusion Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether AstraZeneca is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/fusion-pharmaceuticals-inc-nasdaq-fusn/.
Kinnate Biopharma Inc. (Nasdaq – KNTE)
Under the terms of the agreement, Kinnate will be acquired by XOMA Corporation (“XOMA”) (Nasdaq - XOMA). Kinnate shareholders will receive (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0.2527 per share (together with the Base Price, the Cash Amount) at the closing of the merger plus a non-transferable contingent value right (CVR), representing the right to receive 85% of the net proceeds from any out license or sale of the Kinnate programs effected within one year of closing of the merger or 100% of the net proceeds from any out license or sale executed prior to the closing. The investigation concerns whether the Kinnate Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether XOMA is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/kinnate-biopharma-inc-nasdaq-knte/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
